112.21MMarket Cap-1542P/E (TTM)
1.680High1.620Low1.22MVolume1.620Open1.620Pre Close2.00MTurnover2.36%Turnover Ratio2.36P/E (Static)68.01MShares25.48052wk High0.35P/B85.02MFloat Cap1.57552wk Low--Dividend TTM51.53MShs Float41.930Historical High--Div YieldTTM3.70%Amplitude1.575Historical Low1.645Avg Price1Lot Size
Amylyx Pharmaceuticals Stock Forum
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
Moomoo 24/7· 1 min ago
Relyvrio/Albrioza will no longer be available for new patients as of today; Patients currently on therapy in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program; PHOENIX Open Label Extension is ongoing
No comment yet